Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
STAT+
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharmalot
STAT+

STAT+ Conversations: An update from STAT’s Pharmalot

  • Ed Silverman

By Ed Silverman Oct. 6, 2020

Reprints

Editor’s note: A live stream of the conversation is embedded below.

Each week, STAT Plus subscribers get exclusive access to live discussions with STAT reporters and leaders in health and medicine. For this month only, thanks to Allscripts, we’re inviting all STAT readers to join in on these conversations.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Ed Silverman

Ed Silverman

Pharmalot Columnist, Senior Writer

Ed Silverman covers the pharmaceutical industry.

Tags

Buyer’s remorse: How a Medicare Advantage business is strangling…
Buyer’s remorse: How a Medicare Advantage business is strangling one of its first funders
Vote now in STAT Madness 2023
Vote now in STAT Madness 2023
When women are denied an abortion, their children fare…
When women are denied an abortion, their children fare worse than peers
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings
Pharmalittle: Sanofi cuts price on a popular insulin by…
Pharmalittle: Sanofi cuts price on a popular insulin by 78%; Califf criticizes insurers for doing too…
Sanofi becomes the third leading insulin maker to lower…
Sanofi becomes the third leading insulin maker to lower list prices, cutting Lantus price by 78%

Recommended Stories